Federal Court finds Jamp’s nintedanib capsules to infringe Boehringer’s use patent but not its formulation patent
On August 8, 2024, the Federal Court (per Furlanetto J.) held that a patent directed to nintedanib for use in the prevention or treatment of idiopathic pulmonary fibrosis (“IPF”) was valid and infringed, while a patent directed to formulations of nintedanib was not infringed. Boehringer Ingelheim (Canada) Ltd. et al v. Jamp Pharma Corporation, 2024 […]